Concurrent chemoradiotherapy plus nimotuzumab versus chemoradiotherapy alone for locoregionally advanced nasopharyngeal carcinoma with a suboptimal response to induction chemotherapy: a randomized phase 2 trial
Abstract Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) is the standard treatment for locoregionally advanced nasopharyngeal carcinoma (LA-NPC); however, patients with a suboptimal response to IC, defined as detectable Epstein–Barr virus DNA and/or stable or progressive...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
Nature Portfolio
2026-03-01
|
| Ráidu: | Nature Communications |
| Liŋkkat: | https://doi.org/10.1038/s41467-026-71019-5 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|
